GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: ELLIPTA placebo DPIDevice: DISKUS placebo DPIDevice: HandiHaler placebo DPIOther: Inhaler preference questionnaires
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT03227445
- Locations
- 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States
Daprodustat Hepatic Impairment Study
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT03223337
- Locations
- 🇺🇸
GSK Investigational Site, Orlando, Florida, United States
Qualitative Analysis of Subject Experience of Nasal Polyps
Completed
- Conditions
- Nasal Polyps
- Interventions
- Other: VAS questionnaireOther: SNOT-22 questionnaireOther: Data capture app
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT03221192
- Locations
- 🇺🇸
GSK Investigational Site, Boston, Massachusetts, United States
RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: RELVAR 100 ELLIPTA
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1047
- Registration Number
- NCT03219255
- Locations
- 🇯🇵
GSK Investigational Site, Kanagawa, Japan
A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Test product (Moisturising cream)Other: No treatmentOther: Positive control (Commercial market place moisturising cream)
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 69
- Registration Number
- NCT03216265
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
Study of Renin-angiotensin System in Mechanically Ventilated Subjects
Not Applicable
Terminated
- Conditions
- Acute Lung Injury
- Interventions
- Drug: Local standard of careProcedure: Mechanical ventilation
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 57
- Registration Number
- NCT03212690
- Locations
- 🇫🇷
GSK Investigational Site, Créteil, France
This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
Phase 3
Completed
- Conditions
- Rotavirus VaccinesRotavirus Infection
- Interventions
- Biological: RotarixBiological: PediarixBiological: HiberixBiological: Prevenar 13
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1280
- Registration Number
- NCT03207750
- Locations
- 🇺🇸
GSK Investigational Site, Marshfield, Wisconsin, United States
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 165
- Registration Number
- NCT03207243
- Locations
- 🇺🇦
GSK Investigational Site, Kyiv, Ukraine
GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
Phase 3
Withdrawn
- Conditions
- Psoriasis
- Interventions
- Drug: GSK2894512 1% creamDrug: Vehicle cream
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03202004
A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects
Phase 1
Withdrawn
- Conditions
- Psoriasis
- Interventions
- Drug: GSK2894512 1% CREAMDrug: GSK2894512 MATCHING VEHICLE CREAM
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03201978
© Copyright 2025. All Rights Reserved by MedPath